Purpose of review The purpose of this review is to provide an update on the clinical, public health and economic consequences of Campylobacter infection.
INTRODUCTION
Since its first identification as a human pathogen in the 1970s, Campylobacter has emerged as a leading cause of acute gastroenteritis worldwide. Clinically relevant organisms include Campylobacter jejuni and Campylobacter coli, which are the major pathogens, but several species are recognized causes of illness in humans [1 & ] (Table 1) .
CLINICAL CONSEQUENCES

Acute enteritis
C. jejuni is among the most frequent causes of bacterial gastroenteritis globally [2 && -4 && ]. Using multilocus sequence typing (MLST), more than 8300 C. jejuni sequence types have been described [5 && ]. Although generally considered to cause mild and self-limiting acute enteritis, in a recently completed retrospective cohort study in Sweden more than a quarter (27%) of stool culture positive Campylobacter cases were admitted to hospital [6 & ]. The majority (92%) of the laboratory-confirmed cases were admitted because of severe enteritis or colitis. There was a statistically significant 14-fold increase in risk of hospital admission for people with comorbidities. People infected with C. jejuni sequence type 257 were twice as likely to be admitted to hospital. This study serves as a timely reminder that C. jejuni acute enteritis can be severe.
Chronic sequelae
As well as causing very unpleasant acute symptoms, Campylobacter infection is also associated with various chronic sequelae, although the evidence for an association is stronger for some conditions than others. Campylobacter infection has been implicated in the subsequent development of reactive arthritis (ReA), Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), haemolytic uraemic syndrome (HUS), inflammatory bowel disease (IBD) and functional gastrointestinal disorders (FGID). In a recent systematic review and meta-analysis of 31 observational studies, the proportion of Campylobacter cases developing chronic sequelae was estimated. The proportion of Campylobacter cases that went on to develop ReA was 2.86% [95% confidence interval (CI) ¼ 1. .61%], irritable bowel syndrome (IBS) was 4.01% (95% CI ¼ 1.41-10.88%) and GBS was 0.07% (95% CI ¼ 0.03-0.15%) [7 & ]. Given the overall incidence of Campylobacter infection (see below), these estimates suggest that a considerable number of Campylobacter cases can develop chronic sequelae, but caution is required when interpreting the results because of high heterogeneity between studies.
Reactive arthritis
ReA, formerly known as Reiter's syndrome, is a postinfectious spondyloarthropathy, which occurs around 2-4 weeks after gastrointestinal or genitourinary infections. The pain associated with ReA occurs most often in the knees, ankles and feet. In a systematic review using stringent criteria to define diarrhoea-associated ReA, the weighted mean incidence of ReA following Campylobacter infection was nine per 1000 cases [8] . Further evidence for the contribution of Campylobacter infection to subsequent ReA comes from seroprevalence data. Using an optimized ELISA assay for diagnosing a previous Campylobacter infection, around 53% (44-62%) of ReA cases demonstrated Campylobacter seropositivity (OMP18 and P39 for IgA and in the P39-antigen for IgG) [9] . Polymorphisms in the IL-18 and IFN-g genes appear to be associated with the development of Campylobacter-associated ReA [10] . Symptoms of ReA usually disappear completely within 6 months.
KEY POINTS
Campylobacter is one of the leading bacterial foodborne pathogens worldwide.
Chronic sequelae after Campylobacter infection can be very serious, causing considerable lifelong morbidity.
There is growing evidence of the importance of the interaction of the gut-brain axis, microbiota and immune system in the pathogenesis of irritable bowel syndrome.
C. concisus and C. showae are emerging as potentially important triggers of inflammatory bowel disease.
Preventing Campylobacter infection still relies on the socalled 4Cs -thorough cooking and cleaning (including hands and work surfaces), proper chilling and avoiding cross-contamination. However, in 10-20% of people, the symptoms persist beyond 6 months, although it is said that only a few people develop an ongoing arthritis beyond 12 months requiring longer term treatment. Finally, antibiotic treatment does not appear to improve the outcome in ReA [11] .
Guillain-Barré syndrome
The most severe late consequence of Campylobacter infection is GBS, which is the most frequent cause of acute flaccid symmetrical weakness of the limbs and absence of deep tendon reflexes [12] . The incidence of post-Campylobacter GBS is estimated to be between one in 1000 and one in 5000 cases. It is characterized initially by tingling in the toes, feet and legs, and the fingers, hands and arms. This is followed by ascending muscle weakness and paralysis (not to be confused with the descending paralysis of botulism). Symptoms of GBS can progress very rapidly. The majority of people reach the stage of greatest weakness within the first 2 weeks after symptoms first appear, and by the third week 90% of patients are at their weakest. Approximately 30% of patients with GBS have persisting weakness after 3 years. Around 3% can experience a relapse of muscle weakness and tingling sensations many years after the original episode. The heterogeneity of presenting symptoms presents a considerable challenge in the initial clinical diagnosis of GBS. In a retrospective review of 69 GBS patients presenting to emergency rooms in Texas, atypical clinical signs and symptoms led to delayed diagnosis [13] . In that study, neuropathic pain and the presence of intact deep tendon reflexes were significantly associated with delayed GBS diagnosis. Patients who were assessed by a neurologist during the initial visit experienced significantly better clinical outcomes. However, patients in whom GBS was not suspected during the initial neurology assessment were significantly more likely to need intubation and to have residual weakness at the time of discharge from hospital [13] .
The mechanism of neural damage involves molecular mimicry between C. jejuni and human peripheral nerve proteins [14] . It is known that sialylated lipo-oligosaccharides of C. jejuni are crucial virulence factors for the development of GBS. However, there is now a suggestion that the polysaccharide capsule of C. jejuni is also an important virulence factor [15] . In two geographically distinct GBS-associated C. jejuni strain collections researchers concluded that capsular types HS1/44c, HS2, HS4c, HS19, HS23/36c and HS41 were markers for GBS compared with controls with uncomplicated enteritis [15] . Using MLST, they found restricted genetic diversity for strain populations with HS2, HS19 and HS41 capsular types. Thus, these capsules may also confer susceptibility to GBS.
Management of GBS involves plasmapheresis and high-dose immunoglobulin therapy and supportive treatment, for example mechanical ventilation, prevention of complications such as pneumonia or bed sores and physiotherapy as muscle strength returns. In a Cochrane systematic review of six randomized controlled trials, plasmapheresis was found to help speed recovery from GBS without causing significant harm [16] . The authors concluded that there was moderate-quality evidence showing significantly greater improvement with plasmapheresis than supportive care alone in adults with GBS without a significant increase in serious adverse events. They found a small but significant increase in the risk of relapse during the first 6-12 months after onset in patients treated with plasmapheresis exchange compared with patients not undergoing this treatment. Nevertheless, after 12 months, patients who had undergone plasmapheresis were significantly more likely to recover fully and were less likely to suffer severe residual weakness [16] . More recently, in a Cochrane review of 12 trials, there was moderate quality evidence that, in severe disease, starting intravenous immunoglobulin (IVIg) 2 weeks from onset hastened recovery as much as plasmapheresis [17] . There was also moderate quality evidence that administering IVIg after plasmapheresis did not afford significant additional advantage [17] . Finally, often overlooked features of GBS are fatigue, pain and psychological distress, which can have a considerable impact on health-related quality of life (QoL) [18 & ].
Miller Fisher syndrome MFS is a rare late consequence of Campylobacter infection. Essentially, it is a nonparalytic variant of GBS in which patients present with ophthalmoplegia, ataxia and areflexia. Recently, a new, simple, clinical classification system has been proposed for GBS, MFS and their subtypes to help to facilitate early clinical diagnosis with a view to starting appropriate immunotherapy as rapidly as possible [19 && ].
Haemolytic uraemic syndrome Antecedent Campylobacter infection has been associated with diarrhoea-related HUS. It is believed to be a rare cause of pulmonary-renal syndrome leading to life-threatening pulmonary haemorrhage [20] .
Inflammatory bowel disease
There has been considerable debate over the years about a role for Campylobacter infection in the aetiology of IBD. It has been postulated that in genetically predisposed people, gut microbes, in association with a disrupted gastrointestinal epithelium, can fuel and then drive a dysregulated immune response that results in chronic inflammation in the intestine [21,22 & ]. In a recent systematic review and meta-analysis, the association between IBD and a variety of Campylobacter spp. was investigated [23 && ]. In total, the sample comprised 519 patients with IBD and 1133 non-IBD controls. Overall, there was an almost three-fold increase in risk of IBD following infection with Campylobacter spp. [pooled odds ratio (P-OR) ¼ 2.97, 95% CI ¼ 1.33-6.63, P ¼ 0.008]. In that review, Campylobacter spp. was confirmed in 39% of patients with IBD compared with 13% of non-IBD controls. On stratification by Campylobacter spp., the analyses showed that the organisms chiefly responsible for the observed association with increased risk of IBD were Campylobacter concisus (P-OR: 3.76, 95% CI ¼ 1.46-9.70, P value ¼ 0.006) and Campylobacter showae (P-OR: 2.39, 95% CI ¼ 1.11-5.18, P ¼ 0.027) [23 && ].
Functional gastrointestinal disorders
The link between acute gastroenteritis and subsequent postinfectious IBS has been established for some time, but there are few studies that have quantified pathogen-specific risk. In a retrospective cohort study of FGID amongst the US military, there were statistically significant associations between antecedent Campylobacter infection and the risk of developing postinfectious IBS [adjusted relative risk (aRR) ¼ 2.8, 95% CI ¼ 1.9-4.1], functional dyspepsia (aRR ¼ 2.0, 95% CI ¼ 1.3-3.0), functional constipation (aRR ¼ 1.8, 95% CI ¼ 1.3-2.5) and gastrooesophageal reflux disease (aRR ¼ 1.7, 95% CI ¼ 1.4-2.1) [ 
PUBLIC HEALTH CONSEQUENCES
Illness burden
The population burden of illness associated with Campylobacter infection is very high. On a global scale, Campylobacter spp. are estimated to cause some 96 million (95% uncertainty interval 52-177 million) cases of foodborne illness [4
&&
]. In the United Kingdom, there are some 280 000 cases of Campylobacter foodborne illness [28] , whereas in Canada the estimate is around 145 000 cases [29] .
An increasingly common metric for describing the burden of disease associated with foodborne pathogens is the disability-adjusted life year (DALY), which is a useful method for combining loss of life and health because of illness compared with a 'perfect' state of health, using time as the common measure. In the United States, Campylobacter infection is estimated to cause about 22 500 DALYs annually [30] , whereas in the Netherlands, Campylobacter spp. are responsible for around 3600 DALYs per year [31] .
Outbreaks
The association between eating undercooked poultry and developing Campylobacter infection is well known. However, consuming lightly cooked chicken livers, chicken liver pâté and chicken liver parfait has emerged as important risk factors [32] [33] [34] . Recognizing this emerging trend in the United Kingdom, the Food Standards Agency commissioned research to develop a recipe for manufacturing commercial quantities of chicken liver pâté that reliably kills campylobacters [35 & ]. Further evidence that cooking practices are responsible for Campylobacter cases and outbreaks associated with lightly cooked chicken livers comes from an interdisciplinary study in the United Kingdom [36 & ]. In an online survey, most chefs who took part could correctly identify safely cooked chicken livers. However, they tended to overestimate consumers' preference for 'pinkness' and so chefs tended to serve chicken livers more lightly cooked than the public would have preferred. Moreover, it was estimated that 19-52% of livers served commercially in [37] , and consumption of raw milk (either intentionally or through failure of pasteurization) continues to pose risks for Campylobacter infection [38,39 & ].
Sporadic infection
The majority of Campylobacter cases are unrelated to outbreaks. Newly identified risk factors for sporadic in recently published case-control studies include contact with garden soil for C. jejuni and C. coli, and consuming beef (C. coli only) [40] , and eating cantaloupe and queso fresco (Mexican cheese) [41] . However, consumption of contaminated poultry continues to feature prominently in the epidemiology of sporadic cases [42, 43] . This is not necessarily surprising given the continued high prevalence of contamination of poultry on retail sale [44] . 
Antimicrobial resistance
ECONOMIC CONSEQUENCES
Various researchers have monetized the cost of Campylobacter infection (Table 2) [31, [46] [47] [48] . The estimates of cost vary quite widely reflecting differences in, for example study design, costing elements included and type of healthcare system. Some researchers included in their cost estimates the impact of long-term sequelae, whereas others did not. Despite the differences in study design, the broad message is the same -namely that Campylobacter is a costly infection.
The likely costs of prevention can be hard to estimate but point to the fact that although the savings from prevention would accrue mainly to cases and health services, the costs would lie elsewhere in government and in industry. Nevertheless, in New Zealand, where there has been a considerable effort to reduce Campylobacter contamination of poultry flocks, the benefit : cost ratio was extremely high [49 && ]. The beneficial effect of reduced campylobacteriosis to the New Zealand economy was around NZD 57 million per year. So investing in food safety compliance measures at primary production was very worthwhile [49 && ]. In the absence of such measures in other countries, preventing Campylobacter infection still relies on the so-called 4Cs -thorough cooking and cleaning (including hands and work surfaces), proper chilling and avoiding cross-contamination.
CONCLUSION
Campylobacter causes considerable morbidity worldwide. Postinfectious sequelae mainly affect the gastrointestinal tract (FGID and IBD), the musculoskeletal system (ReA) and the peripheral nervous system (GBS and MFS), and these sequelae can lead to lifelong disability and reduction in health-related QoL. The economic costs of Campylobacter infection are very high for cases, the healthcare system and for society in general. However, in general, prevention still depends on tried and tested methods, that is, good food (and personal) hygiene. 
